cases per million, is considered a rare disorder according to the US rare disorder act. 2, 3, 4 Males and females are affected equally, with a mean age at diagnosis of 42 yr in men and 44 yr in women. The true incidence and prevalence of the condition in Canada is unknown. Nevertheless, the diagnosis is often delayed because the clinical signs and symptoms evolve slowly. Indeed, the average interval from onset of symptoms to diagnosis is 8.7 yr. 4 Normalization of IGF-I blood levels improves the clinical signs and symptoms of the disease and results in a mortality rate that does not differ from that of the normal population. [5] [6] [7] [8] These benefits make tight control of the GH/IGF-I axis a requirement of therapy today. [9] [10] [11] [12] [13] [14] Current Canadian consensus guidelines recommend that patients with acromegaly should first undergo surgery, which usually provides a good chance of full remission with 60 to 80% success rate for micradenomas and approximately 40% for macroadenomas. 6, [15] [16] [17] Acromegalic patients not cured by surgery alone and who also failed somatostatin analogues are considered candidates for the addition of a dopamine agonist, a GH receptor antagonist, or switched to a GH receptor antagonist. 15 Pegvisomant is the first of a class of novel GH receptor antagonists. In Canada, this medication is indicated for the treatment of acromegaly in patients who have had an inadequate response to the conventional therapy, or for whom these therapies are not appropriate. 18 Pegvisomant selectively binds to GH receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction. Inhibition of GH action results in decreased IGF-I levels. 18 Early clinical trials established that daily rather than weekly subcutaneous (sc) administration was the most appropriate pegvisomant dosing frequency. [19] [20] [21] [22] [23] A 12-week, Phase III, multi-center placebo controlled clinical trial in 112 acromegalic patients found that pegvisomant daily doses of 10, 15, and 20 mg were effective in controlling biochemical abnormalities and clinical signs and symptoms of acromegaly. 24, 25 Pegvisomant reduced IGF-I blood level in a dosedependent fashion with nearly 80% of patients reaching adjusted normalized IGF-I levels at Week 12. 18 This control continued for at least another 6 months of pegvisomant treatment, suggesting a lack of tachyphylaxis. 26 Information regarding long-term safety and efficacy remains quite limited. 27 Here, we report on pegvisomant safety, tolerability and efficacy outcomes from phase 4, compassionateuse, multi-centre, open-label, variable dose long-term study in acromegalic patients refractory to conventional therapy.
Methods

Study Population
Enrolment consisted of acromegalic subjects who were responsive to pegvisomant during previous studies and had completed the entire course of the study, or subjects who were shown to be unresponsive or intolerant to conventional pharmacotherapy (somatostatin analogue or somatostatin analogue along with a dopamine agonist) based on the investigator's assessment and who were ineligible to participate in other pegvisomant trials.
Key exclusion criteria included visual field loss, cranial nerve palsies or intracranial hypertension requiring tumour decompression surgery and clinically significant hepatic disease and/or alanine amino transferase (ALT)/aspartate amino transferase (AST) elevation >3 times upper limits of normal (ULN). Other exclusion criteria were a history of hypersensitivity to any components of pegvisomant, including latex; inability to fully comprehend the nature of the study, or cooperate with study procedures; subjects refusing to use adequate contraception to prevent pregnancy during the study; subjects unwilling or unable to selfadminister study medication on a daily basis; known or suspected drug / alcohol abuse; pregnant or lactating women; severe acute or chronic medical or psy-chiatric condition or laboratory abnormality that could increase the risk associated with trial participation.
Study Design
The trial was an open-label, non-randomized, singlearm, variable dose study of pegvisomant. The primary objective of this study was to provide pegvisomant on a compassionate-use basis to Canadian refractory acromegalic patients and measure patient's IGF-I levels to normalize signs and symptoms of acromegaly. The secondary outcome measures were to evaluate pegvisomant safety and tolerability, and collect efficacy data.
Efficacy data were assessed by means of acromegaly signs and symptoms scales which measured how patients rated the severity of the pain during the last 7 days. Administration of signs and symptoms of acromegaly questionnaire was assessed as of the baseline visit, then at each study visit at approximately 3-month intervals, and finally at the end of treatment visit. Items 1-5, i.e. headache, perspiration, arthralgia, fatigue, and soft tissue swelling, recorded severity of symptoms and are assessed on a scale of 0 (Absent) to 8 (Severely incapacitating). Patients overall health status (item 6) was scored from 0 (worst possible) to 10 (best possible). Serum IGF-I concentration was also assessed every 3 months, and shorter intervals (4-6 weeks) were recommended for dose adjustments in order to maintain IGF-I levels within the age-adjusted normal range and alleviate the signs and symptoms of acromegaly.
Safety data, including treatment-emergent adverse events (AEs), subject discontinuations due to AEs, and withdrawals were collected. All observed AEs were assessed by Investigators for severity and relationship to the pegvisomant therapy. In the study protocol, an AE was defined as any untoward medical occurrence in a study subject administered pegvisomant, which did not necessarily have a causal relationship with the treatment or usage. AEs were classified as mild, moderate or severe. Specifically, AE of mild severity does not interfere with subject's usual function; an AE of moderate intensity interferes to some extent with subject's usual function; and an AE of severe grade interferes significantly with subject's usual function.
The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines, the Declaration of Helsinki and applicable local regulatory requirements and laws. It was approved by the institutional review board or independent ethics committee of each participating center.
Study treatment
Pegvisomant (Somavert; Pfizer Canada) is a sterile, white lyophilized powder intended for sc injection after reconstitution with sterile water for injection. Treatment with pegvisomant started at the baseline visit. Subjects who were naïve to pegvisomant began daily subcutaneous injections of 10 mg. Subjects at stable doses who completed previous pegvisomant trials were continued at their individualized stable dose. Maximum dosing could not exceed 30 mg/day. The pegvisomant dosing regimen was adjusted by increments of 5 mg/day if IGF-I levels were within 20% below or 20% greater than the ULN. In the event of a reduction in IGF-I below the lower limit of normal (LLN), the dose of pegvisomant could be decreased by 5 mg/day.
Laboratory Assessments
Alkaline phosphatase (ALP), AST, ALT, total bilirubin (TBIL), and glucose analyses were measured at regular intervals. The following criteria were used to describe abnormal findings: 1) results which were associated with symptoms; 2) results requiring additional diagnostic testing or medical/surgical intervention; and/or 3) result leading to a change in pegvisomant dosing or discontinuation from the study.
Safety Evaluations
Additional safety assessments included: 1) periodic imaging scans of the pituitary fossa to assess possible tumour growth, 2) monitoring of glucose and doses of anti-diabetic medications, 3) clinical signs and symptoms of a GH/IGF-I-deficient state. In such an event, the pegvisomant dose would be adjusted to maintain IGF-I within the age-adjusted normal range.
Statistical Analysis
Data are presented using descriptive statistics including means, standard deviation, median, minimum and maximum for each study visit. Categorical data were also presented using descriptive statistics (e.g., percentage and absolute frequencies). In these analyses, missing values were handled using the last observation carried forward (LOCF) methodology, (i.e. wherever the relevant result was missing the nearest (preceeding) post-baseline result was used in the analysis). The full analysis set included all subjects who took at least one dose of the study medication and had a postbaseline efficacy measure (at least one assessment with acromegaly Signs and Symptoms Questionnaire or IGF-I post-baseline score). For reporting purposes, the overall health status and each sign and symptom of questionnaire were evaluated separately. Serum IGF-I level and acromegaly questionnaires were collected to document responses and make doseadjustments. IGF-I serum level was converted into sex-and age-adjusted IGF-I standard deviation score (SDS) and a paired t-test was performed comparing baseline with follow-up timepoints. No adjustments for multiple comparisons were performed and the paired t-test was a post-hoc analysis.
Safety parameters included treatment-emergent AEs, including analysis of serious adverse events (SAEs), medical history and concomitant medications, withdrawals from the study and subject discontinuations due to AEs. The number and percentage of subjects experiencing treatment-emergent AEs were presented for the safety analysis set i.e. those subjects who received at least one dose of pegvisomant in the context of this particular study. The incidence of treatment-emergent AEs was tabulated by dose and prior to tabulation all adverse events were coded into MedDRA preferred terms. The incidence of serious adverse events was also tabulated.
Results
Baseline patient characteristics
A total of 19 patients with persistently active acromegaly despite previous pituitary surgery and/or medical therapy were enrolled. All patients had pituitary adenomas except for one who suffered from McCune Albright syndrome which, due to fibrous dysplasia, precluded pituitary surgery. There were 10 males and 9 females with a mean age of 41.0 and 45.6 yr respectively. Overall, the mean weight for male and female patients was 120.2 and 96.1 kg, respectively. The mean weight and height of all subjects was 108.8 kg and 176.7 cm, respectively (Table 1) . Two subjects withdrew consent choosing not to participate in the trial, and 2 others were discontinued due to hepatic Ezzat et al. Pegvisomant in refractory acromegaly As outlined in Table 2 , in addition to previous surgery and medical therapy, 26.3% (5/19) of patients had received previous radiotherapy, which was completed at least one year before study entry. Table 2 depicts the previous medications used for acromegaly management. All 12 somatostatin analoguereceiving patients continued with their anti-pituitary tumor therapy. Those receiving the dopamine agonists cabergoline (n=3) or bromocriptine (n=1) discontinued this class of therapy. A total of 7/19 patients were on previous pegvisomant clinical trials and continued on pegvisomant. Treatment for pre-existing diabetes was required in 4 subjects which included both insulin and oral hypoglycaemic agents.
Previous and Concomitant Medications
Clinical Efficacy
At each study visit subjects completed the Signs and Symptoms of Acromegaly Questionnaire. This information is summarized and presented by overall health status ( Figure 1) .
For individual symptoms, among the most salient clinical features of acromegaly, soft tissue swelling was the most frequently controlled feature. Perspiration and headaches were also relatively wellcontrolled. In contrast, joint pains and fatigue were more difficult to manage and, overall, there was a slight tendency towards these features remaining relatively unaffected in this group of patients with refractory acromegaly. From a subjective perspective, the overall health status scores ( Figure 1 ) indicated that there were no subjects rating their overall health as "the best possible" neither at baseline nor at study visit 4, nor at the final visit. The number of subjects who rated their overall health as "bad and very bad" (scored from 5 to 8) at baseline was 12, which comprised the majority of the study population.
Biochemical Efficacy
Given that IGF-I is an integrated measure of 24 hour GH secretion which varies with age, Figure 2 represents changes in circulating IGF-I levels depicted as standard deviation scores. Mean values decreased during the study, with significant values shown from month-6 and throughout the course of the study, with the nadir for mean IGF-I occurring after 18 months of pegvisomant continuous treatment. In fact, mean IGF-I score steadily decreased over time from baseline (mean ± SE: 3.29 ± 0.42) to 18 months (mean ± SE: 1.50 ± 0.38, P=0.0010 vs. baseline) and 27 months (mean ± SE: 1.66 ± 0.36, P=0.0003 vs. baseline) post-study start. Importantly, there was no evidence of tachyphylaxis with sustained IGF-I reduction throughout the study with a median of 548 days of follow-up. The longest duration of treatment was documented in 2 subjects of 889 and 909 days respectively. Three subjects were treated for more than 6 months but less than a year. One of these latter subjects withdrew his consent on the 217 th day post-study treatment citing the inconvenience of daily injections. The daily dosage of the pegvisomant injections ranged from 10 mg/day to 30 mg/day (mean ± SE: 17.7 ± 1.35 mg/day). One subject administered the treatment in an atypical regimen, which was: 30 mg of pegvisomant once a week for approximately 5 months, and then 15 mg twice a week for about 1.5 months. In 17 of the 19 treated subjects the dose of pegvisomant was increased during the trial to achieve optimal IGF-I reduction and control of clinical features of acromegaly. Of note, one subject had his pegvisomant dosage decreased from 20 to 15 mg daily due to decrease in IGF-I levels below normal range.
Adverse events
As outlined by Table 3 , the majority of adverse events were of a mild-to-moderate nature (reported in 22 and 63 instances respectively out of 114 total instances), and the minority of severe intensity (reported in 29/ 114 instances). The most common AEs were those considered inherent to the disease including: fatigue (5 AEs reported in 3 subjects), increased weight (11 AEs described in 5 subjects), joint swelling (specifically reported in 1 subject), headache (7 AEs noted in 5 subjects), arthralgia (reported in 2 subjects), and de novo development of achrocordon, splenomegaly and carpal tunnel syndrome (each occurred in 1 subject).
Of the 19 subjects that received the study treatment, 2 were permanently discontinued due to liver enzyme elevation (non-serious in nature; specific enzymes and values were not reported). One subject experienced liver test abnormalities on the 535 th day and recovered on the 595 th day post-study treatment initiation. related to the study drug. Another subject with an augmentation of liver enzymes had her AE started on 72 nd day and resolved on 122 nd day post-study treatment initiation. The event was considered to be of moderate severity and related to the study treatment. The 2 patients with increased liver enzymes were not considered to be serious adverse events (SAEs) as predefined by the study protocol and were also receiving octreotide in combination with pegvisomant, which suggests it may be related to the drug combination, rather than monotherapy. There were no deaths during the study. Of the 6 SAEs reported in 5 subjects, none were assessed as related to the study treatment as determined by the Investigator. The following SAEs were reported during the study: Sinusitis (1); transmission of drug via semen (1); blood pressure decrease (1) and uterine leiomyoma (1); atrial fibrillation (1) that resolved with pharmacological intervention; diverticulitis (1) .
There was a single incident of syncope considered possibly related to hypoglycemia in a non-diabetic patient. One diabetic insulin-treated patient developed symptomatic hypoglycemia necessitating pegvisomant dose reduction.
Overall, the safety profile of the pegvisomant therapy was found to be satisfactory and suitable for a long-term treatment. The study subjects demonstrated a good tolerability to pegvisomant, for a long duration of the therapy.
Discussion
As illustrated by our current patient cohort, active acromegaly is associated with increased risk of comorbid disease including diabetes, hypertension, heart failure, osteoarthritis, and sleep apnea. 28 If left suboptimally controlled, the disease typically results in reduced survival by almost a decade. Thus, an aggressive approach to normalize IGF-1 levels has become standard of care. Treatment options include combinations of neurosurgical, medical, and/or radiotherapeutic approaches. 15 Here, we show that patients who have failed surgical and conventional medical therapies can be successfully treated with the GH receptor .3) 0 1 0 * In the study protocol, a treatment-emergent adverse event was defined as any untoward medical occurrence in a study subject administered pegvisomant, which did not necessarily have a causal relationship with the treatment or usage. NOTE: If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is reported. Subjects are counted only once per treatment in each row. For the TESS algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was recorded. In this case, the reported severity is summarized. Missing baseline severities are imputed as mild. Includes data up to 999 days after last dose of study drug. MedDRA (v10.0) coding dictionary applied. * In the study protocol, a treatment-emergent adverse event was defined as any untoward medical occurrence in a study subject administered pegvisomant, which did not necessarily have a causal relationship with the treatment or usage. NOTE: If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is reported. Subjects are counted only once per treatment in each row. For the TESS algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was recorded. In this case, the reported severity is summarized. Missing baseline severities are imputed as mild. Includes data up to 999 days after last dose of study drug. MedDRA (v10.0) coding dictionary applied. * In the study protocol, a treatment-emergent adverse event was defined as any untoward medical occurrence in a study subject administered pegvisomant, which did not necessarily have a causal relationship with the treatment or usage. NOTE: If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is reported. Subjects are counted only once per treatment in each row. For the TESS algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was recorded. In this case, the reported severity is summarized. Missing baseline severities are imputed as mild. Includes data up to 999 days after last dose of study drug. MedDRA (v10.0) coding dictionary applied. * In the study protocol, a treatment-emergent adverse event was defined as any untoward medical occurrence in a study subject administered pegvisomant, which did not necessarily have a causal relationship with the treatment or usage. NOTE: If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is reported. Subjects are counted only once per treatment in each row. For the TESS algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was recorded. In this case, the reported severity is summarized. Missing baseline severities are imputed as mild. Includes data up to 999 days after last dose of study drug. MedDRA (v10.0) coding dictionary applied. * In the study protocol, a treatment-emergent adverse event was defined as any untoward medical occurrence in a study subject administered pegvisomant, which did not necessarily have a causal relationship with the treatment or usage. NOTE: If the same subject in a given treatment had more than one occurrence in the same preferred term event category, only the most severe occurrence is reported. Subjects are counted only once per treatment in each row. For the TESS algorithm any missing severities have been imputed as severe unless the subject experienced another occurrence of the same event in a given treatment for which severity was recorded. In this case, the reported severity is summarized. Missing baseline severities are imputed as mild. Includes data up to 999 days after last dose of study drug. MedDRA (v10.0) coding dictionary applied.
antagonist pegvisomant. This effectiveness was evidenced not only by reduction but through strict ageadjusted normalization of IGF-I levels. Importantly, these IGF-I reductions were accompanied by measureable symptomatic improvements.
The physiologic rationale for the use of pharmacotherapy in acromegaly is well founded. Somatostatin analogs (SSA) are based principally on the inhibitory effects of endogenous somatostatin on GH secretion. Although the first generation SSAs required up to three administrations a day, the newer formulations are longer acting and require intramuscular or deep subcutaneous injections once monthly. The first analogs had extended half-lives compared with the native hormone but of only two hours and requiring sc administration at least three times daily. 29 This class of analogs successfully reduces GH and IGF-I levels in 50 to 70% of patients. However, IGF-I normalization has been reported in only 30-50% of patients who have failed pituitary surgery. 30 Our current data highlight the clinical significance of persistently elevated IGF-I levels in patients with acromegaly despite SSA therapy.
The effectiveness of SSA in achieving biochemical remission was assessed in a meta-analysis of 44 trials. 30 Criteria for efficacy of treatment with somatostatin LAR generally involved normalization of IGF-I but also a mean GH less than 2.5 ng/ml and/or a GH less than 1 ng/ml during an OGTT. Among all subjects treated with octreotide-LAR, 57% had normalization of GH, with 67% having normalization of IGF-I. Treatment with octreotide-LAR was generally more effective than with lanreotide-SR, which resulted in GH and IGF-I normalization in 48 and 47% of patients respectively. Clearly, patients who do not achieve IGF-I normalization, as illustrated by the current study, should be considered for additional therapy.
Pegvisomant is a recombinantly-derived analog of human GH which acts as a highly selective growth hormone receptor (GHR) antagonist. 24, 26 Competing effectively with endogenous GH, pegvisomant interrupts GH receptor dimerization to impede intracellular signaling. Such signaling interruption in the liver impairs production of IGF-I which is the main source of the circulating growth factor. 21 Treatment with pegvisomant results in a dose-dependent reduction of IGF-I levels but a rise in circulating GH levels. Therefore, serum IGF-I, and not GH, as performed in the current study, are used to monitor the response to therapy.
Two larger studies have been conducted to assess long-term effects of pegvisomant therapy in acromegaly. Trainer et al. conducted a double-blinded randomized placebo-controlled trial of 111 acromegalic patients who received treatment for 12 weeks with placebo or one of three doses of pegvisomant including 10, 15, or 20 mg administered subcutaneously once a day. 24 Patients treated with the highest dose had a reduction of IGF-I levels of up to 60% and a normalization of IGF-I in 89% of cases. These patients also experienced a reduction in their symptom and sign scores in a dose-dependent manner. In a follow-up to this first study, 152 patients were treated with pegvisomant for up to 18 months. 26 In the group of patients treated for 12 months, IGF-I was normalized in 97% of patients, reflecting a success rate higher than other existing pharmacotherapies. In addition to the reduction in IGF-I, there was a parallel increase in GH that plateaued by 6 months of pegvisomant treatment. GH levels increased 12-14 µg/L on average. This increase in GH concentration is the result of cross-reactivity by the assay of the drug. It may also reflect increased pituitary GH secretion due to interrupted negative feedback resulting from diminished IGF-I production. Our current study extends on these observations by demonstrating the sustained reduction of IGF-I over years.
A concern with GH receptor antagonism is the potential for pituitary tumour expansion. Although no significant increase in tumor volume was noted overall, two patients withdrew due to an increase in tumour volume. 26 Although it is not known whether tumour growth can be directly attributed to pegvisomant administration, unlike SSAs, this medication does not have tumour anti-proliferative effects. Therefore, patients receiving the GH receptor antagonist require close observation. In the current study, we did not observe radiographic evidence for pituitary tumour remnant re-growth or expansion. Nevertheless, such GH antagonism is not advisable as first-line pharmacological therapy in patients with large macroadenomas or those in whom their tumors are in close proximity to the optic chiasm. In summary our study demonstrates the role of combination SSA-GH antagonist therapy in effectively normalizing IGF-I levels in patients who are not biochemically controlled with SSAs alone. However, few studies have specifically compared the independent and combined effects of these two forms of medical therapy. Earlier retrospective studies hinted at more effective lowering IGF-I lowering compared with either agent alone. 31 However, in a more recent study focused on those who were resistant to SSA, the combination of two agents was equally as effective as pegvisomant alone in reducing IGF-I levels 32 Furthermore, co-administration of pegvisomant with SSA appears to increase pegvisomant levels while at the same time decreasing GH levels compared to pegvisomant therapy alone. The addition of weekly pegvisomant therapy at a mean dose of 60 mg per week for 42 weeks resulted in normalization of IGF-I in 95% of patients. No increase in tumour size was seen, but mild increases in liver enzymes were noted in 38% of patients. Thus, based on the literature and the data reported in the current study several conclusions can be made. Patients exhibiting partial sensitivity to SSA, the addition of weekly pegvisomant therapy should be considered along with follow-up of hepatic function. Those showing more complete resistance to SSA should be considered for pegvisomant monotherapy. Such recommendations should optimize IGF-I responses and tumour size restraint with cost-effective, fiscally responsible long-term treatment plans. Alternatively, by adding pegvisomant to SSA, the total cost may also be reduced as both agents are typically administered at reduced doses with similar or improved efficacy compared with monotherapy.
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